Abstract
Despite decades of research on necrotizing enterocolitis (NEC), the outlook for infants afflicted by this devastating disease is all too often bleak. The aim of this symposium at the BAPS conference in Amsterdam was to highlight recent advances in the knowledge of the epidemiology and diagnosis of NEC. There were important contributions on the disease in the United Kingdom, both from a neonatal and a surgical point of view, whereas colleagues from the Netherlands and elsewhere in Europe shared their insights into novel diagnostic tools, both biofluid and imaging based.
Necrotizing enterocolitis needs no introduction to the paediatric surgeon. The presentation of a sick premature neonate who has been tolerating enteral feeds but has developed abdominal distension, increased aspirates and has pneumatosis intestinalis and pneumoperitoneum is all too familiar, as are the findings at laparotomy -necrotic bowel requiring extensive resection, and the outcomes -mortality, neurodevelopmental impairment and short bowel syndrome [1] . Probiotics have not eradicated the disease [2] and the surgical outcomes do not appear to have improved over twenty years [3, 4] , so research into the epidemiology and rapid diagnosis of the disease is urgently required.
Although animal models have been used and novel therapies suggested in these models, careful clinical research continues to deliver important data which can hopefully help paediatric surgeons to improve outcomes. The aim of the Symposium at the BAPS Congress in Amsterdam was to provide the paediatric surgeons faced with this disease up-to date information about the epidemiology of NEC across the UK, and novel data on biomarkers and physiological measurements that colleagues in Europe are using to shed light on how intervention might be made in a more timely manner in the future.
Epidemiology
Although comprehensive data on NEC incidence and/or surgical outcomes is available from some counties, areas, or healthcare systems, including population-based data from Sweden [5] and the Vermont-Oxford Network Hull VON [6] , data from the UK has been lacking, except for a survey study of 158 NICUs [7] . The UK National Confidential Enquiry into Patient Outcome and Death report on paediatric surgery in 2011 highlighted the gaps in our knowledge about incidence, epidemiology and outcomes of NEC in the UK [8] , and following this two national prospective studies were initiated to fill some of these gaps. The UK Neonatal NEC Study, slightly misleadingly, covered England only, but prospectively acquired data from all from all 163 neonatal units between December 2011 and September 2014 and will provide an important neonatal perspective on risk factors and antecedent feeding practices. Professor Neena Modi, from Imperial College London, gave a sneak preview into these as yet unpublished data, including the development of a consistent case-definition tool for surveillance, and we look forward to the publication of these important data. The other UK study presented at the meeting, the British Association of Paediatric Surgeons Congenital Anomalies Surveillance System (BAPS-CASS) Surgical NEC study, did indeed cover the whole of the UK and Ireland by collecting data from 28 neonatal surgical centres over one year. This study complements the neonatal study by providing data on surgical management and outcomes of those infants that required surgery. Miss Kokila Lakhoo presented the data from this study on behalf of BAPS-CASS, which showed that 236 infants required surgery in the UK over one year, and highlighted the variation in surgical practices. In part, this variation is due to the heterogeneity of disease in terms of presentation and area of intestine affected, but also is a result of the lack of evidence for the optimal surgical management. |We also eagerly look forward to publication of the BAPS-CASS study. In both epidemiological studies, infants were identified who died without having surgery. can these markers be used for early diagnosis?; (ii) can they predict severity of disease?; and (iii) can they be used to guide the re-introduction of enteral feeds? Ernst showed us that the combination of I-FABP and calprotectin gave the highest accuracy in the diagnosis of NEC [9] , that SAA together with platelets were the most predictive of surgical NEC [10] and that I-FABP can be useful to direct re-feeding following surgery [11] . However, use of these markers is only useful if the turnaround time by hospital laboratories is fast enough for them to be used in clinical decision making and it remains to be seen whether these markers will enter widespread clinical practice. Circulating cytokines are markers of systemic immune status, and pro-inflammatory cytokines have long been known to be elevated in NEC. There has been limited information, however, on whether cytokine measurements can be useful in diagnosis or risk assessment in NEC [12] , and this was the topic of the presentation by Thomas Benkoe, from Vienna. Using a cytokine array to measure pro-inflammatory (IL-1b, IL-2,IL-5,IL-6, IL-8, IL-12, IFNgamma, TNF-alpha, TNF-beta) and anti-inflammatory cytokines (IL-4, IL-10), only IL-10,IL-8 and IL-6 were shown to be significantly higher in surgical NEC than in matched controls [13] , similar findings on IL-6 and IL-8 being reported by others [14] [15] .
Thomas then focussed in on IL-8, which is a chemoattractant for neutrophils and macrophages whose intestinal expression has been linked with NEC [16] , and showed that IL-8 is a suitable marker for preoperative risk assessment, that IL-8 levels obtained within 6 hours prior to surgery correlate with the actual intraoperative disease extent [17] and that high levels correlate with 60-day mortality [18] . Interestingly, although IL-8 is in theory non-specific, whereas I-FABP discussed above is specific for the gut, IL-8 may in fact be a better marker than I-FABP [19] . In Thomas' hospital, and potentially many others, IL-8 is available as a routine test, so unlike many laboratory-based biomarkers, might prove to be clinically useful, although precise cutoffs and criteria for intervention must be developed. Of course, imaging methodologies have the potential advantage of either real-time information, or at least a faster reporting time than measurement of biomarkers in body fluids, at least until one of these biomarkers is adopted for a point-ofcare test. Jan Hulscher, from Groningen, has been exploring the use of near infra-red spectroscopy (NIRS) in NEC, and shared his data in his symposium talk. NIRS provides a non-invasive measurement of tissue oxygen saturation, which potentially allows a realtime window into intestinal perfusion, which is measured as tissue fractional oxygen saturation after taking into account arterial saturation concomitantly measured by pulse oximetry. Although one might assume that in NEC infants, intestinal perfusion would be lower in infants predisposed to NEC, in fact Jan showed that cerebral oxygenation, rather than intestinal oxygenation, is impaired in the first days of life in infants that go on to get NEC, whereas intestinal perfusion is impaired immediately preceding clinical NEC [20] .
In a further study, although NIRS could not distinguish between definite NEC and absence of NEC, it could differentiate between complicated from uncomplicated NEC [21] . Encouragingly, these differences in NIRS readings also correlated well with I-FABP levels, thus validating the use of NIRS to examine intestinal impairment [22] .
However, Jan stressed that at the present time, because of the high variability, NIRS was currently useful to examine the pathogenesis of NEC at a group level, but that it was not currently ready for prime-time on an individual patient basis, in other words the holy grail of indicating which infants require urgent surgical intervention.
